The Protein Is An Immunoglobulin Patents (Class 800/6)
-
Publication number: 20120222140Abstract: The present invention provides a human artificial chromosome vector comprising a gene encoding the human antibody heavy chain, a gene encoding the human antibody light chain, and a gene encoding IgM heavy chain constant region derived from a nonhuman animal; and being capable of producing a human antibody with a higher efficiency when the vector is introduced into an animal. By immunizing the animal produced using a human artificial chromosome vector of the present invention with a desired antigen, a large quantity of human polyclonal antibodies can be supplied.Type: ApplicationFiled: November 17, 2010Publication date: August 30, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Yoshimi Kuroiwa, Hiroaki Matsushita, Akiko Sano
-
Patent number: 8241626Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: October 3, 2006Date of Patent: August 14, 2012Assignee: Agensys, Inc.Inventors: Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Daniel E. H. Afar, Steven Chappell Mitchell, Mary Faris, Aya Jakobovits
-
Publication number: 20120198575Abstract: This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.Type: ApplicationFiled: April 5, 2012Publication date: August 2, 2012Inventors: Paul F. Agris, Christopher D.J. Pearce, Lloyd G. Mitchell
-
Patent number: 8232449Abstract: The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.Type: GrantFiled: February 17, 2011Date of Patent: July 31, 2012Assignee: Medarex, Inc.Inventors: Dawn M. Tanamachi, Peter Brams, Amelia Black
-
Publication number: 20120157667Abstract: Provided herein are methods of reconstituting functional human blood cell lineages in a non-human mammal comprising introducing human hematopoietic stem cells (HSCs) and nucleic acid encoding one or more human cytokines into an immunodeficient non-human mammal. The non-human mammal is maintained under conditions in which the nucleic acid is expressed and the human HSCs differentiate into functional human blood cell lineages in the non-human mammal, thereby reconstituting functional human blood cell lineages in the non-human mammal. Also provided are methods of producing human antibodies directed against an immunogen in a non-human mammal, hybridomas that secrete the monoclonal antibodies as well as antibodies (e.g., polyclonal antibodies; monoclonal antibodies) produced by the B cells and non-human mammals produced by the methods.Type: ApplicationFiled: June 28, 2010Publication date: June 21, 2012Inventors: Qingfeng Chen, Jianzhu Chen
-
Publication number: 20120151611Abstract: The present invention aims to provide a method for antibody preparation. The present invention is directed to a method for preparing an antibody-producing cell, which comprises the following steps: (1) transplanting metastatic cancer cells capable of expressing a target antigen into a non-human animal to ensure engraftment of the cancer cells in the animal; (2) immunizing the animal with the target antigen; and (3) collecting the antibody-producing cell from the immunized animal; as well as a method for preparing an antibody, which comprises collecting the antibody from the antibody-producing cell prepared by the above method.Type: ApplicationFiled: August 24, 2011Publication date: June 14, 2012Inventors: Hiroyuki Satofuka, Masahiro Uchino, Shingo Hanaoka
-
Publication number: 20120148490Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: ApplicationFiled: December 1, 2011Publication date: June 14, 2012Inventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne NcNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Publication number: 20120151610Abstract: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework ?-pleated sheet leading to increased net hydrophobicity within FR1 and an increased number of charged amino acids present in FR3. Also provided are VII domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.Type: ApplicationFiled: March 19, 2010Publication date: June 14, 2012Applicant: ERASMUS UNIVERSITY MEDICAL CENTERInventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Tao Chen, Ernie De Boer
-
Patent number: 8173860Abstract: The invention provides, in part, methods for the production of proteins in a transgenic non-human mammal, wherein the proteins are transported from the blood to the mammary gland for secretion in milk. The transport of the protein to the mammary gland and/or milk is facilitated by binding to a transport receptor in the mammary gland.Type: GrantFiled: April 20, 2007Date of Patent: May 8, 2012Assignee: GTC Biotherapeutics, Inc.Inventors: Harry M. Meade, Daniel Pollock
-
Publication number: 20120047586Abstract: Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.Type: ApplicationFiled: October 23, 2008Publication date: February 23, 2012Applicant: Otsuka Chemical Co., LtdInventors: Takashi Tsuji, Yasuhiro Kajihara, Katsunari Tezuka, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Patent number: 8088617Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.Type: GrantFiled: January 24, 2008Date of Patent: January 3, 2012Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Aaron Sato, Maureen Fitch-Bruhns
-
Patent number: 8067665Abstract: A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.Type: GrantFiled: August 12, 2009Date of Patent: November 29, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kiyoshi Habu, Kou-ichi Jishage, Hideki Adachi, Naohiro Yabuta
-
Patent number: 8021662Abstract: Methods for production of tumor-specific antibodies are provided. The methods employ microorganisms that are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proliferating tissues, particularly tumors, to produce selected proteins and other products.Type: GrantFiled: April 25, 2007Date of Patent: September 20, 2011Assignee: Genelux CorporationInventors: Aladar A. Szalay, Tatyana Timiryasova, Yong A. Yu, Qian Zhang
-
Patent number: 7964767Abstract: Membrane proteins that are background antigens were solubilized, and transgenic animals were produced using genes encoding these soluble proteins. Antibodies against the background antigen membrane proteins comprised in the immunogens were not found in these transgenic animals, and even when genes encoding soluble proteins were used, immunotolerance against the full-length membrane proteins could be induced. Moreover, by expressing the background antigen membrane proteins as soluble proteins inside the bodies of transgenic animals, unfavorable phenotypes that appear when the full-length membrane proteins are expressed could be avoided, and such animals were made widely available as immunized animals.Type: GrantFiled: March 31, 2005Date of Patent: June 21, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsuhiko Kodama, Yoshiki Yamada, Nobuo Kamada, Kou-Ichi Jishage
-
Publication number: 20110145937Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and/or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable/mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided.Type: ApplicationFiled: December 10, 2010Publication date: June 16, 2011Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Sean Stevens, Andrew J. Murphy
-
Publication number: 20110138489Abstract: The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.Type: ApplicationFiled: February 17, 2011Publication date: June 9, 2011Inventors: Dawn M. Tanamachi, Peter Brams, Amelia Black
-
Patent number: 7928285Abstract: In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein.Type: GrantFiled: June 25, 2008Date of Patent: April 19, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: James M. Robl, Yoshimi Kuroiwa, Poothappillai Kasinathan, Isao Ishida, Kazuma Tomizuka
-
Patent number: 7919672Abstract: The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several human or humanized immunoglobulin transloci. This can be done by overexpressing the apoptosis inhibitor, i.e. a rabbit bcl-2, whose expression is driven by a B-cell specific promoter specifically in the B-cell of the animal, thereby enhancing the survival of B-cells. This invention further relates to a method for selectively enhancing the survival of exogenous B-cells, that is B-cells expressing any immunoglobulin transgene locus, over the survival of endogenous B-cells that do not express the transgene locus. Selectivity is achieved by expressing the apoptosis-inhibitor only within exogenous B-cells, that is, by coupling exogenous immunoglobulin expression with apoptosis inhibitor expression.Type: GrantFiled: August 2, 2006Date of Patent: April 5, 2011Assignee: Therapeutic Human Polyclonals, Inc.Inventors: Roland Buelow, Josef Platzer
-
Patent number: 7919674Abstract: It is an object of the present invention to provide a high affinity antibody effective as a diagnostic or therapeutic for various diseases; a transgenic mammal for producing the high affinity antibody; and a medicine comprising the high affinity antibody or a cell producing the high affinity antibody. According to the present invention, a transgenic mammal carrying a GANP gene transferred thereinto, its progeny, or a part thereof, and a method of producing a high affinity antibody using the same are provided.Type: GrantFiled: November 7, 2003Date of Patent: April 5, 2011Assignee: Immunokick IncorporationInventor: Nobuo Sakaguchi
-
Patent number: 7910798Abstract: The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.Type: GrantFiled: March 30, 2007Date of Patent: March 22, 2011Assignee: Medarex, Inc.Inventors: Dawn M. Tanamachi, Peter Brams, Amelia Black
-
Publication number: 20110067122Abstract: The present invention relates to the production of a transgenic ungulate which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies.Type: ApplicationFiled: February 9, 2009Publication date: March 17, 2011Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: James M. Robl, Richard A. Goldsby, Stacy E. Ferguson, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida, Barbara A. Osborne
-
Publication number: 20110055938Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.Type: ApplicationFiled: August 11, 2010Publication date: March 3, 2011Inventors: WILLIAM DON HARRIMAN, ROBERT ETCHES, PHIL LEIGHTON
-
Publication number: 20110010781Abstract: The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor ?-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.Type: ApplicationFiled: November 17, 2009Publication date: January 13, 2011Inventors: Mamoru Ito, Kimio Kobayashi, Tatsutoshi Nakahata, Koichiro Tsuji, Sonoko Habu, Yoshio Koyanagi, Naoki Yamamoto, Kazuo Sugamura, Kiyoshi Ando, Tatsuji Nomura
-
Publication number: 20100330095Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: ApplicationFiled: November 12, 2008Publication date: December 30, 2010Applicant: U3 PHARMA GMBHInventors: Thore Hettmann, Jens Niewoehner, Jens Ruhe, Peter Wirtz, Kerstin Selle, Esther Zwick-Wallasch, Mike Rothe
-
Publication number: 20100333220Abstract: A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.Type: ApplicationFiled: August 12, 2009Publication date: December 30, 2010Inventors: Kiyoshi Habu, Kou-ichi Jishage, Hideki Adachi, Naohiro Yabuta
-
Publication number: 20100306863Abstract: A TREM-1 ligand is identified. This allows various derivatives to be provided/identified that are capable of binding to the TREM-1 receptor. The TREM-1 ligand or the derivatives can be used in screening for drugs/drug candidates. Substances that block or reduce binding of the TREM-1 ligand/derivative to a TREM-1 receptor may be useful for treating sepsis, particularly sepsis of bacterial or fungal origin. Antibodies to the ligand may be useful in diagnosing sepsis, particularly sepsis of bacterial or fungal origin.Type: ApplicationFiled: July 23, 2008Publication date: December 2, 2010Inventors: Marco Colonna, Julia Klesney-Tait, Paola Panina
-
Publication number: 20100306864Abstract: Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.Type: ApplicationFiled: October 23, 2008Publication date: December 2, 2010Applicant: Otsuka Chemical Co., LtdInventors: Takashi Tsuji, Yasuhiro Kajihara, Katsunari Tezuka, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Patent number: 7820877Abstract: The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and V?) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.Type: GrantFiled: October 14, 2005Date of Patent: October 26, 2010Assignee: Amgen Fremont Inc.Inventors: Aya Jakobovits, Raju Kucherlapati, Sue Klapholz, Michael J. Mendez, Larry Green
-
Patent number: 7812215Abstract: Methods of producing protein using a recombinant ovomucoid gene expression controlling region operably linked to one or more useful amino acid coding sequences.Type: GrantFiled: November 17, 2008Date of Patent: October 12, 2010Assignee: Synageva BioPharma Corp.Inventors: Alex J. Harvey, Markley C. Leavitt, Youliang Wang
-
Publication number: 20100209346Abstract: The invention relates to neuromodulatory oligomers of the amyloid ?(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers and diagnostic and therapeutic agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof.Type: ApplicationFiled: September 14, 2009Publication date: August 19, 2010Inventors: Heinz Hillen, Andreas Striebinger, Carsten Krantz, Achim Moeller, Reinhold Mueller
-
Publication number: 20100205679Abstract: Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.Type: ApplicationFiled: December 12, 2008Publication date: August 12, 2010Inventors: Sanford M. Simon, Yu Chen
-
Publication number: 20100186100Abstract: Peptide antigens corresponding to amino acid residues 2-12, 1-12, 2-15 and 1-15 of parathyroid hormone (PTH), antibodies having an affinity to such peptide antigens and methods of producing the same. Such antigens, antibodies and methods producing the same according to the present invention are useful in determining bioactive intact PTH levels in serum, plasma, and/or cell culture media. Such antibodies further possess a high degree of species cross-reactivity, but substantially mitigated cross-reactivity to non-whole PTH peptide fragments and little to no recognition of the first amino acid residue of PTH.Type: ApplicationFiled: February 19, 2010Publication date: July 22, 2010Inventors: RICHARD J. ZAHRADNIK, JEFFREY R. LAVIGNE
-
Patent number: 7750204Abstract: This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has been introduced. Since immunotolerance to the background antigens have thus been induced in the transgenic animals, the animals efficiently produce antibodies to target antigens.Type: GrantFiled: June 4, 2003Date of Patent: July 6, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsuhiko Kodama, Kou-Ichi Jishage, Nobuo Kamada, Yoshiki Yamada
-
Patent number: 7736648Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.Type: GrantFiled: October 24, 2008Date of Patent: June 15, 2010Assignee: Trellis Bioscience, Inc.Inventors: Lawrence M. Kauvar, Ellen J. Collarini, Bruce Keyt, Orit Foord
-
Patent number: 7727531Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.Type: GrantFiled: October 24, 2008Date of Patent: June 1, 2010Assignee: Valorisation-Recherche, Societe En commanditeInventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
-
Patent number: 7662375Abstract: The present invention relates to the use of antibodies against glucose-6-phosphate isomerase (GPI) and like protein for diagnosis of arthritis and the use of said protein for treatment of arthritis. It is also aimed at a process for isolating monoclonal antibodies capable of transferring arthritis and antibodies thereof, as well as a method for determining the anti-arthritis potential of a composition.Type: GrantFiled: February 24, 2006Date of Patent: February 16, 2010Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Christophe Benoist, Isao Matsumoto, Anne-Sophie Korganow, Diane Mathis, Mariana Maccioni, Hong Ji
-
Publication number: 20090317386Abstract: The present invention relates to the identification of a novel mechanism of transcription infidelity in cells. The invention provides compositions and methods to detect the level of transcript ion infidelity in a sample, as well as the use thereof, e.g., for therapeutic, diagnostic, pharmacogenomic or drug design. As will be disclosed, the invention is particularly suited for detecting, monitoring or treating proliferative cell disorders, for the design and/or screening of drugs, for patient or disease profiling, prediction of disease severity and evaluation of drug efficacy.Type: ApplicationFiled: July 20, 2007Publication date: December 24, 2009Applicant: TRANSMEDI SAInventor: Bernard Bihain
-
Publication number: 20090312526Abstract: The present invention relates to a method for producing antibodies and to antibodies produced by this method. In one embodiment the invention relates to a method for producing an antibody that binds to a polypeptide of a first species, the method comprising immunizing a mammal of a second species with cells derived from a transgenic mammal of the second species, wherein the polypeptide of the first species is expressed on the surface of the cells derived from the transgenic mammal.Type: ApplicationFiled: August 22, 2007Publication date: December 17, 2009Applicant: G2 INFLAMMATION PTY LTD.Inventor: Charles Reay Mackay
-
Publication number: 20090304683Abstract: The invention relates to the spike protein from the virus (SARS-CoV) that is etiologically linked to severe acute respiratory syndrome (SARS); polypeptides and peptide fragments of the spike protein; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and coupled proteins that include the spike protein or a portion thereof; peptidomimetics; vaccines; methods for vaccination and treatment of severe acute respiratory syndrome; antibodies; aptamers; and kits containing immunological compositions, or antibodies (or aptamers) that bind to the spike protein.Type: ApplicationFiled: January 19, 2007Publication date: December 10, 2009Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Zhu Zhongyu
-
Publication number: 20090307787Abstract: The present invention relates to a method for the generation of VH heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a VH heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous VH heavy chain locus in that mammal.Type: ApplicationFiled: January 25, 2007Publication date: December 10, 2009Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens
-
Publication number: 20090297526Abstract: The present invention includes polypeptides, polynucleotides encoding the polypeptides, antibodies to the polypeptides, and methods for using the polypeptides and antibodies. The polypeptides include those with at least 80% identity to Rickettsia prowazekii TIyC or PId.Type: ApplicationFiled: June 8, 2006Publication date: December 3, 2009Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Ted J. Whitworth, Donald H. Bouyer, David H. Walker
-
Publication number: 20090288177Abstract: A targeting vector was constructed by replacing exon regions in the SGRF gene with appropriate drug marker genes. This vector was transfected into mouse ES cell lines to obtain chimeric mice, which were then crossed with C57BL/6J mice to obtain mice comprising cells in which one SGRF gene alleles was inactivated. By crossing these mice with each other, the present inventors succeeded in producing mice in which both SGRF gene alleles were inactivated. These genetically modified animals can be used to predict the side effects of drugs such as SGRF antagonists.Type: ApplicationFiled: July 8, 2009Publication date: November 19, 2009Inventors: Kiyoshi Habu, Yuichi Hirata
-
Publication number: 20090271880Abstract: The present invention relates to methods for engineering VH domains to improve their solubility and stability. The invention provides for the incorporation of defined amino acid substitutions based on 3-D structural information into the V segments of a heavy chain locus, expressing the locus in a non-human mammal and selecting soluble VH domains. Further stabilising or solubilising mutations maybe introduced as a result affinity maturation during B-cell maturation in vivo.Type: ApplicationFiled: September 18, 2007Publication date: October 29, 2009Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek
-
Publication number: 20090260093Abstract: The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.Type: ApplicationFiled: March 30, 2007Publication date: October 15, 2009Inventors: Dawn M. Tanamachi, Peter Brams, Amelia Black
-
Patent number: 7601818Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.Type: GrantFiled: July 15, 2004Date of Patent: October 13, 2009Assignees: Amgen, Inc., Medarex, Inc.Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
-
Publication number: 20090255002Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: ApplicationFiled: September 26, 2008Publication date: October 8, 2009Inventors: Nils Lonberg, Robert M. Kay
-
Publication number: 20090232734Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.Type: ApplicationFiled: March 27, 2009Publication date: September 17, 2009Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Ngo
-
Publication number: 20090222935Abstract: In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein.Type: ApplicationFiled: June 25, 2008Publication date: September 3, 2009Inventors: James M. Robl, Yoshimi Kuroiwa, Poothappillai Kasinathan, Isao Ishida, Kazuma Tomizuka
-
Patent number: 7576258Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: GrantFiled: September 30, 2005Date of Patent: August 18, 2009Assignees: Medarex, Inc., Kyowa Hakko Kirin Co., Ltd.Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
-
Publication number: 20090196872Abstract: Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. A human monoclonal antibody that binds to influenza M2 protein having different amino acid sequences. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.Type: ApplicationFiled: December 5, 2005Publication date: August 6, 2009Applicant: KIRIN BEER KABUSHIKI KAISHAInventors: Shinichiro Kato, Rongfang Wang